ArticleJAMA oncology2016

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Sarat Chandarlapaty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.